TrialCurrent oncology (Toronto, Ont.)2021

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer.

Megan M Tu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.